June 24th 2020, 7:51pm
The neoadjuvant combination of nivolumab and ipilimumab continues to demonstrate a benefit in RFS compared with the combination given in the adjuvant setting in patients with stage III macroscopic melanoma.
June 24th 2020, 7:25pm
The FDA has approved pembrolizumab (Keytruda) for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.
June 23rd 2020, 6:46pm
June 23rd 2020, 2:20pm
Jeffrey S. Weber, MD, PhD, discusses research efforts examining neoadjuvant approaches in melanoma.
June 9th 2020, 2:07am
Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.
June 8th 2020, 11:53pm
Alexander Eggermont, MD, PhD, discusses the impact of the 3-year follow-up data from the phase 3 double-blind EORTC 1325/KEYNOTE-054 trial in high-risk stage III melanoma.
June 8th 2020, 10:55pm
Charles L. Sawyers, MD, provides additional insight into the IMspire150 and SWOG S1320 trials presented at the 2020 AACR Annual Virtual Meeting I and underscored the need for additional research in this space.
June 8th 2020, 6:57pm
June 6th 2020, 7:00pm
Presented by Dr. Mark Agulnick, MD from Northwestern University, please join us on July 8, 2020 at 8 PM EDT for a presentation on an FDA-approved treatment option for use in patients with advanced CSCC.
June 4th 2020, 11:51pm
In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.
